Second-tier Congenital Adrenal Hyperplasia (CAH)  
Proficiency Testing Program (PT)  
2017 Quarter 4 November

Introduction
This report is the Quarterly summary of CAHPT data reported within the specified data-reporting period for Quarter 4, 2017. Reports are distributed to all participants, state laboratory directors, and program colleagues by request. The tables within this report provide certification information for the proficiency testing (PT) specimen panel, statistical analysis of reported quantitative data, and the frequency distribution summaries for expected interpretations. An evaluation of your reported data is attached to this summary.

Certification of PT Specimens
The dried blood spot (DBS) PT specimens were prepared at 50% hematocrit, with different enrichments of five biomarkers for congenital adrenal hyperplasia (CAH); 17 α-hydroxyprogesterone (17OHP), 4-androstenedione (4AD), cortisol (Cort), 11-deoxycortisol (11D), 21-deoxycortisol (21D). Expected values (sum of endogenous and enrichment values) were determined by EIA (17OHP only) and LC-MS/MS. For determination of the Clinical Assessment (CA) NSQAP applies the formula: clinical ratio = ([17OHP] + [4AD])/[CORT]. A cutoff of 1.0 is used to assess whether the specimen is Within Normal Limits (1) or Outside Normal Limits (2).

Table 1. Expected Values (ng/mL serum) and Expected Clinical Assessments (CA)

<table>
<thead>
<tr>
<th>Specimen</th>
<th>EIA</th>
<th>LC-MS/MS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>17OHP</td>
<td>4AD</td>
</tr>
<tr>
<td>417A1</td>
<td>7.9</td>
<td>9.1</td>
</tr>
<tr>
<td>417A2</td>
<td>55.9</td>
<td>63.9</td>
</tr>
<tr>
<td>417A3</td>
<td>7.9</td>
<td>8.7</td>
</tr>
<tr>
<td>417A4</td>
<td>57.1</td>
<td>40.0</td>
</tr>
<tr>
<td>417A5</td>
<td>66.5</td>
<td>70.4</td>
</tr>
</tbody>
</table>

1 = Within Normal Limits  2 = Outside Normal Limits  NE = Not Evaluated
Distribution of PT Specimens

On October 2, 2017, a PT panel of DBS specimens was distributed to 6 domestic laboratories and 28 international laboratories.

Participant Results

٧ Quantitative Data

We received data from 21 participants by the data reporting deadline. Laboratories were asked to report concentrations of 17OHP, 4AD, Cort, 11D, and 21D analyzed by Second-tier LC-MS/MS and EIA (optional). For the statistical summary analysis, we did not include data that were outside the 99% confidence interval.

All data are presented in units of ng/mL serum. Participants whose methods yield data in nM whole blood units were asked to multiply by the following factors for conversion to serum concentration: 0.66 (17OHP), 0.57 (4AD), 0.72 (CORT), and 0.69 (11D and 21D). Data that are not submitted in the requested units (ng/mL serum) are not accepted. Conversion factors are provided on the CAHPT Data Report Form.

Twenty-one laboratories reported results using tandem mass spectrometry (LC-MS/MS). Twelve of these labs also reported enzyme immunoassay (EIA) results. The expected analyte concentration values were based on CDC expected values. Overall statistics from EIA (Table 2) and LC-MS/MS (Table 3) methods were combined so as to not identify an individual laboratory.

Table 2. Overall statistics—17OHP (ng/mL serum) by EIA

<table>
<thead>
<tr>
<th>Specimen</th>
<th>N</th>
<th>Mean</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>417A1</td>
<td>12</td>
<td>9.2</td>
<td>2.5</td>
</tr>
<tr>
<td>417A2</td>
<td>12</td>
<td>63.3</td>
<td>14.4</td>
</tr>
<tr>
<td>417A3</td>
<td>12</td>
<td>9.2</td>
<td>2.8</td>
</tr>
<tr>
<td>417A4</td>
<td>12</td>
<td>40.7</td>
<td>6.8</td>
</tr>
<tr>
<td>417A5</td>
<td>12</td>
<td>66.4</td>
<td>11.9</td>
</tr>
</tbody>
</table>

Table 3. Overall statistics — 17OHP, 4AD, Cort, 11D, 21D (ng/mL serum) by LC-MS/MS

<table>
<thead>
<tr>
<th>Specimen</th>
<th>17OHP N</th>
<th>Mean</th>
<th>SD</th>
<th>4AD N</th>
<th>Mean</th>
<th>SD</th>
<th>Cort N</th>
<th>Mean</th>
<th>SD</th>
<th>11D N</th>
<th>Mean</th>
<th>SD</th>
<th>21D N</th>
<th>Mean</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>417A1</td>
<td>18</td>
<td>13.38</td>
<td>10.2</td>
<td>18</td>
<td>20.03</td>
<td>4.4</td>
<td>18</td>
<td>40.17</td>
<td>9.9</td>
<td>13</td>
<td>7.31</td>
<td>3.6</td>
<td>11</td>
<td>1.34</td>
<td>1.4</td>
</tr>
<tr>
<td>417A2</td>
<td>21</td>
<td>63.10</td>
<td>14.6</td>
<td>21</td>
<td>26.11</td>
<td>6.0</td>
<td>21</td>
<td>123.35</td>
<td>22.5</td>
<td>13</td>
<td>7.00</td>
<td>3.2</td>
<td>11</td>
<td>1.26</td>
<td>1.4</td>
</tr>
<tr>
<td>417A3</td>
<td>18</td>
<td>22.75</td>
<td>41.0</td>
<td>18</td>
<td>21.17</td>
<td>4.0</td>
<td>18</td>
<td>43.30</td>
<td>9.8</td>
<td>13</td>
<td>56.35</td>
<td>14.3</td>
<td>13</td>
<td>9.88</td>
<td>3.5</td>
</tr>
<tr>
<td>417A4</td>
<td>21</td>
<td>50.23</td>
<td>22.6</td>
<td>21</td>
<td>26.68</td>
<td>5.4</td>
<td>21</td>
<td>108.49</td>
<td>22.9</td>
<td>13</td>
<td>8.05</td>
<td>3.1</td>
<td>11</td>
<td>1.42</td>
<td>1.6</td>
</tr>
<tr>
<td>417A5</td>
<td>21</td>
<td>72.02</td>
<td>16.2</td>
<td>21</td>
<td>40.04</td>
<td>8.6</td>
<td>21</td>
<td>18.47</td>
<td>5.3</td>
<td>13</td>
<td>16.40</td>
<td>3.6</td>
<td>13</td>
<td>10.99</td>
<td>3.7</td>
</tr>
</tbody>
</table>

2 of 5
Qualitative Clinical Assessments

Qualitative assessments may differ by participant because of specific assessment practices. The frequency distribution of participants’ Clinical Assessments for screening results is shown in Table 4.

Most programs use a clinical ratio to determine if samples are normal or abnormal. Samples with a calculated ratio less than the cutoff are considered “normal”; those samples with a calculated ratio greater than the cutoff are evaluated as “abnormal.” LC-MS/MS cutoff values are summarized in Table 5.

<table>
<thead>
<tr>
<th>Specimen</th>
<th>Within Normal Limits (WNL)</th>
<th>Outside Normal Limits (ONL)</th>
<th>Not Reported (NR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>417A1</td>
<td>17</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>417A2</td>
<td>19</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>417A3</td>
<td>14</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>417A4</td>
<td>17</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>417A5</td>
<td>1</td>
<td>20</td>
<td>0</td>
</tr>
</tbody>
</table>

Table 5.  LC-MS/MS Clinical Ratio Cutoff Values

<table>
<thead>
<tr>
<th>Specimen</th>
<th>All Laboratories</th>
<th>Domestic</th>
<th>International</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEAN</td>
<td>1.91</td>
<td>1.38</td>
<td>2.09</td>
</tr>
<tr>
<td>MODE</td>
<td>1.00</td>
<td>1.00</td>
<td>2.50</td>
</tr>
<tr>
<td>MIN</td>
<td>0.10</td>
<td>1.00</td>
<td>0.10</td>
</tr>
<tr>
<td>MAX</td>
<td>9.00</td>
<td>2.50</td>
<td>3.75</td>
</tr>
</tbody>
</table>

Evaluations

Participants reported 14 False-positive results and one False-negative result based on the LC-MS/MS final Clinical Assessment.
Future Shipments

The Newborn Screening Quality Assurance Program will ship next quarter’s PT specimens for CAHPT in January 2018.

Direct Inquiries

If you have any comments or questions about CAHPT MS/MS analysis, contact Dr. Joanne V. Mei at 770-488-7945 or by e-mail at jvm0@cdc.gov

For data reporting questions, contact Irene Williams at nsqapdmt@cdc.gov

The content of this report may also be located on our website at: http://www.cdc.gov/labstandards/nsqap_reports.html
This NEWBORN SCREENING QUALITY ASSURANCE PROGRAM report is an internal publication distributed to program participants and selected program colleagues. The laboratory quality assurance program is a project cosponsored by the Centers for Disease Control and Prevention (CDC) and the Association of Public Health Laboratories.

CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) ATLANTA, GA 30341

Acting Director
Brenda Fitzgerald, M.D.

Director
National Center for Environmental Health
Patrick Breysse, Ph.D.

Director
Division of Laboratory Sciences
James L. Pirkle, M.D., Ph.D.

Chief
Newborn Screening and Molecular Biology Branch
Carla Cuthbert, Ph.D.

Contributors:
Carter Asef
John Bernstein
Quan Bui
Paul Dantonio
Sharon Flores
Elizabeth M. Hall
Christopher Haynes, Ph.D.
Brandon Kenwood
Francis Lee, Ph.D.
Lixia Li, Ph.D.
Timothy Lim, Ph.D.

Daniel Mandel, Ph.D.
Joanne Mei, Ph.D.
Kristina Mercer
Gyliann Peña
Konstantinos Petritis, Ph.D.
Sean Scott
Robert Vogt, Ph.D.
Irene Williams
Sophia Winchester
Golriz Yazdanpanah
Sherri Zobel

Production:
Sarah Brown
Kimberly Coulter

Kizzy Stewart

ASSOCIATION OF PUBLIC HEALTH LABORATORIES SILVER SPRING, MD 20910

President
Ewa King, PhD

Chairman, Newborn Screening and Genetics in Public Health Committee
Michele Caggana, Sc.D., FACMG

Chairman, Newborn Screening Quality Assurance Quality Control Subcommittee
Patricia R. Hunt, B.A. and Joseph Orsini, Ph.D.

Chairman, Newborn Screening Molecular Subcommittee
Rachel Lee, Ph.D.

INQUIRIES TO:
Irene Williams, Editor • Centers for Disease Control and Prevention (CDC) • Newborn Screening Quality Assurance Program
Mailstop F-24 • 4770 Buford Highway, N.E. • Atlanta, GA 30341-3724
Phone (770) 488-4582 • NSQAPDMT@cdc.gov
E-mail: IWilliams1@cdc.gov